BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 25005336)

  • 1. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report.
    Danve A; Perry L; Deodhar A
    Semin Arthritis Rheum; 2014 Oct; 44(2):195-7. PubMed ID: 25005336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
    Staveri C; Karokis D; Liossis SC
    Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
    Ruiz-Irastorza G; Danza A; Khamashta M
    Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
    Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
    Furer V; Zisman D; Pokroy-Shapira E; Molad Y; Elkayam O; Paran D
    Scand J Rheumatol; 2016; 45(2):103-6. PubMed ID: 26515057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
    Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report.
    Fontana F; Alfano G; Leonelli M; Cerami C; Ligabue G; Spinella A; Citriniti G; Manzini CU; Ferri C; Cappelli G
    BMC Nephrol; 2018 Oct; 19(1):276. PubMed ID: 30342482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belimumab for the treatment of pediatric patients with lupus nephritis.
    Stohl W; Kwok A
    Expert Opin Biol Ther; 2023 Mar; 23(3):243-251. PubMed ID: 36750049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case report of two systemic lupus erythematosus pregnancies with early placental exposure to belimumab: Case report with review.
    Nakai T; Ikeda Y; Yamaguchi K; Asano T; Iwata F; Kidoguchi G; Fukui S; Ozawa H; Kawaai S; Kitada A; Suda M; Nomura A; Tamaki H; Okada M
    Mod Rheumatol Case Rep; 2023 Jan; 7(1):82-86. PubMed ID: 36029470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Belimumab throughout 2 Consecutive Pregnancies in a Patient with Systemic Lupus Erythematosus.
    Kumthekar A; Danve A; Deodhar A
    J Rheumatol; 2017 Sep; 44(9):1416-1417. PubMed ID: 28864669
    [No Abstract]   [Full Text] [Related]  

  • 17. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
    Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
    van Schaik M; Arends EJ; Soonawala D; van Ommen E; de Leeuw K; Limper M; van Paassen P; Huizinga TWJ; Toes REM; van Kooten C; Rotmans JI; Rabelink TJ; Teng YKO
    Trials; 2022 Nov; 23(1):939. PubMed ID: 36371234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab.
    Guzman M; Hui-Yuen JS
    Drug Des Devel Ther; 2020; 14():2503-2513. PubMed ID: 32612353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
    Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
    Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.